Skip to content

MM120 (lysergide D-tartrate) Receptor Binding and Evaluation in the Rat Following 13-weeks of Administration

J. Tripp, G. Smagin

European Psychiatry June 1, 2026 DOI: 10.1192/j.eurpsy.2026.11606 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical animal study Peer reviewed
Population Rats
Intervention MM120 (lysergide D-tartrate
Dose 0, 0.5, 2.0, 6.0 mg/kg daily or 6.0 mg/kg weekly
Duration 13 weeks
Measures functional observational battery (FOB), [3H]8-OH-DPAT binding, [3H]Ketanserin binding
Topics LSD
Key points Chronic daily MM120 at 6 mg/kg downregulated 5-HT2A receptors in rat cortex and hippocampus and also lowered 5-HT1A receptor density, whereas 5-HT1A receptors were unaffected at lower daily doses and weekly 6 mg/kg dosing. The authors argue that 5-HT2A receptor downregulation may underlie tolerance after repeated dosing and suggest reduced abuse potential.

Abstract

Introduction: MM120 (lysergide D-tartrate, LSD, CAS 32426-57-6) is under development as a potential treatment for generalized anxiety disorder and major depressive disorder. MM120 may elicit profound lasting psychological changes through interaction with brain 5-HT1A, 1B, 2A, 2C, 6 and 7 receptors, among others, while the complete mechanism is not clear.

Objectives: The study was performed to determine receptor occupancy and receptor density for 5-HT2A and 5-HT1A receptor in rats after chronic administration of MM120.

Methods: Rats were administered MM120 (0, 0.5, 2.0, 6.0 mg/kg) daily or weekly (6.0 mg/kg) for 13-weeks and tested for toxicity, neurological safety (functional observational battery [FOB]) or physiological states. 5-HT2A and 5-HT1A ex vivo receptor occupancy (RO) was measured by incubation of brain sections with [3H]8-OH-DPAT or [3H]Ketanserin and quantification of binding. Receptor density was then measured in cortical and hippocampal washed membranes.

Results: Chronic dosing showed no changes in body temperatures or FOB at week 13. Body weight changes were lower for 6 mg/kg daily group, but not weekly. Receptor density showed significantly lower binding of [3H]Ketanserin at 6 mg/kg daily (p < 0.05), compared to vehicle and 6 mg/kg weekly groups, indicating a lower 5-HT2AR density. 5-HT1AR density revealed with [3H]8-OH-DPAT binding was significantly lower in 6 mg/kg daily (p < 0.05) group, while other groups were unaffected. in vitro receptor binding and functional activity was evaluated and compared to other drugs of abuse. Chronic administration of MM120 at all doses significantly downregulated 5-HT2ARs in cortex and hippocampus, while 5-HT1ARs were affected only at the 6 mg/kg dose. Image 1: Image 1: Long description.A bar graph showing 5-H T sub 2 A receptor density in rat cortex across different doses and frequencies of a treatment compared to a vehicle control. See long description. Image 2: Image 2: Long description.A bar graph showing 5-H T sub 1 A receptor density in rat cortex across different doses and frequencies of a compound. See long description.

Conclusions: The study demonstrates that 5-HT2AR downregulation may be responsible for the tolerance development after the repeated dosing and reduced abuse potential of MM120. Disclosure of Interest J. Tripp Shareolder of: 100%, Employee of: 100%, G. Smagin Shareolder of: 100%, Employee of: 100%

Comparable studies

Other preclinical and animal studies on LSD, most cited first.

Study Year Design Participants
Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex Human embryonic kidney 293 cells stably expressing 5-HT2ARs; wild-type and 5-HT2AR... 2003 Experimental study
Evidence for a central 5‐hydroxytryptamine receptor stimulation by lysergic acid diethylamide Rats 1968 Experimental study
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression Rats 2020 Preclinical study
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Male mice 2021 Multidisciplinary experimental study with in vivo electrophysiology, optogenetics, behavioral paradigms, molecular biology, and conditional knockout mice
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Mice and cultured rat cortical neurons 2023 Preclinical study

Explore topics